Cyclopharm Crescita futura

Future criteri di controllo 5/6

Cyclopharm prevede che gli utili e i ricavi cresceranno rispettivamente di 104.9% e 42.7% all'anno. Si prevede che l'EPS crescerà di 104.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.2% in 3 anni.

Informazioni chiave

104.9%

Tasso di crescita degli utili

104.3%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	16.2%
Tasso di crescita dei ricavi	42.7%
Rendimento futuro del capitale proprio	13.2%
Copertura analitica	Low
Ultimo aggiornamento	27 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Previsioni di crescita degli utili e dei ricavi

ASX:CYC - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	67	11	9	13	1
12/31/2025	47	-2	-2	1	1
12/31/2024	28	-11	-13	-12	1
6/30/2024	24	-9	-13	-12	N/A
3/31/2024	26	-7	-10	-10	N/A
12/31/2023	27	-5	-8	-7	N/A
9/30/2023	29	-6	-8	-7	N/A
6/30/2023	30	-7	-8	-7	N/A
3/31/2023	27	-7	-8	-7	N/A
12/31/2022	25	-7	-8	-7	N/A
9/30/2022	24	-5	-6	-4	N/A
6/30/2022	23	-4	-4	-2	N/A
3/31/2022	21	-4	-3	-2	N/A
12/31/2021	20	-5	-3	-2	N/A
9/30/2021	20	-5	-5	-4	N/A
6/30/2021	20	-4	-7	-6	N/A
3/31/2021	19	-5	-8	-8	N/A
12/31/2020	18	-6	-9	-9	N/A
9/30/2020	17	-6	-7	-7	N/A
6/30/2020	16	-6	-6	-5	N/A
3/31/2020	17	-4	-3	-3	N/A
12/31/2019	17	-3	-1	0	N/A
9/30/2019	16	-3	-1	0	N/A
6/30/2019	16	-2	-1	0	N/A
3/31/2019	16	-1	-1	-1	N/A
12/31/2018	16	0	-2	-1	N/A
9/30/2018	16	0	-2	-1	N/A
6/30/2018	16	-1	-1	0	N/A
3/31/2018	16	-1	N/A	0	N/A
12/31/2017	16	-2	N/A	-1	N/A
9/30/2017	15	-1	N/A	0	N/A
6/30/2017	14	-1	N/A	0	N/A
3/31/2017	15	0	N/A	0	N/A
12/31/2016	15	1	N/A	1	N/A
9/30/2016	14	3	N/A	2	N/A
6/30/2016	14	5	N/A	4	N/A
3/31/2016	13	5	N/A	4	N/A
12/31/2015	13	5	N/A	4	N/A
9/30/2015	12	4	N/A	4	N/A
6/30/2015	11	3	N/A	4	N/A
3/31/2015	11	4	N/A	4	N/A
12/31/2014	12	4	N/A	4	N/A
9/30/2014	13	-2	N/A	3	N/A
6/30/2014	14	-8	N/A	2	N/A
3/31/2014	13	-9	N/A	1	N/A
12/31/2013	12	-10	N/A	1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CYC diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che CYC diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede CYC diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CYC ( 42.7% all'anno) crescerà più rapidamente del mercato Australian ( 5.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CYC ( 42.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di CYC sarà basso tra 3 anni ( 13.2 %).

Cyclopharm Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 13%

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 14%

Consensus EPS estimates fall by 11%

Forecast breakeven date pushed back to 2025

Consensus estimates of losses per share improve by 13%

Recent updates

New minor risk - Market cap size

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

New 90-day high: AU$3.10

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

New 90-day high: AU$2.63

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

New 90-day high - AU$1.59

First half earnings released

Previsioni di crescita degli utili e dei ricavi